Osmotica Pharmaceuticals (OSMT) stock price, revenue, and financials

Osmotica Pharmaceuticals market cap is $316.1 m, and annual revenue was $263.70 m in FY 2018

$316.1 M

OSMT Mkt cap, 11-Feb-2020

$65.5 M

Osmotica Pharmaceuticals Revenue Q3, 2019
Osmotica Pharmaceuticals Gross profit (Q3, 2019)38.1 M
Osmotica Pharmaceuticals Gross profit margin (Q3, 2019), %58.3%
Osmotica Pharmaceuticals Net income (Q3, 2019)-112.7 M
Osmotica Pharmaceuticals EBIT (Q3, 2019)-123 M
Osmotica Pharmaceuticals Cash, 30-Sept-201998 M
Osmotica Pharmaceuticals EV489.9 M

Osmotica Pharmaceuticals Revenue

Osmotica Pharmaceuticals revenue was $263.70 m in FY, 2018

Embed Graph

Osmotica Pharmaceuticals Revenue Breakdown

Embed Graph

Osmotica Pharmaceuticals revenue breakdown by business segment: 9.4% from Lorzone, 7.8% from Divigel, 40.4% from Venlafaxine ER, 18.4% from Methylphenidate and 24.0% from Other

Osmotica Pharmaceuticals Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

Revenue

170.5m237.7m263.7m

Revenue growth, %

39%

Cost of goods sold

125.6m125.2m135.0m

Gross profit

44.9m112.5m128.7m

Gross profit Margin, %

26%47%49%

R&D expense

29.1m42.7m48.8m

General and administrative expense

66.0m57.0m74.2m

Operating expense total

103.4m99.6m227.2m

Depreciation and amortization

21.5m73.0m

EBIT

(32.0m)(52.1m)(98.5m)

EBIT margin, %

(19%)(22%)(37%)

Interest expense

20.2m29.1m20.8m

Pre tax profit

(52.1m)(85.6m)(118.7m)

Income tax expense

(10.2m)(40.5m)(9.3m)

Net Income

(41.8m)(45.2m)(109.4m)

Quarterly

USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

53.7m66.3m57.1m57.5m65.5m

Cost of goods sold

21.5m32.0m29.2m32.6m27.3m

Gross profit

32.3m34.3m27.9m24.9m38.1m

Gross profit Margin, %

60%52%49%43%58%

R&D expense

6.5m13.3m9.8m5.4m8.3m

General and administrative expense

13.3m17.5m21.7m25.5m24.8m

Operating expense total

19.8m30.8m31.4m156.6m161.1m

Depreciation and amortization

30.7m6.2m

EBIT

(18.2m)(2.6m)(3.5m)(131.7m)(123.0m)

EBIT margin, %

(34%)(4%)(6%)(229%)(188%)

Interest expense

7.3m5.3m4.5m4.6m4.5m

Pre tax profit

(24.3m)(7.5m)(7.4m)(136.3m)(127.3m)

Income tax expense

(12.0m)(2.5m)(1.2m)(11.7m)(14.6m)

Net Income

(12.3m)(5.0m)(6.2m)(124.7m)(112.7m)

Osmotica Pharmaceuticals Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018

Cash

19.6m34.7m70.8m

Accounts Receivable

43.7m37.6m56.4m

Prepaid Expenses

9.5m25.8m20.7m

Inventories

19.8m17.0m24.4m

Current Assets

94.2m115.1m172.4m

PP&E

27.7m31.4m31.3m

Goodwill

152.8m152.8m100.9m

Total Assets

978.5m885.7m795.6m

Accounts Payable

35.0m36.1m24.9m

Short-term debt

5.3m6.7m1.9m

Current Liabilities

117.8m124.7m114.4m

Long-term debt

323.7m313.9m266.9m

Total Debt

328.9m320.6m268.8m

Total Liabilities

513.3m466.4m409.4m

Common Stock

525.2k

Additional Paid-in Capital

489.9m

Retained Earnings

274.8k(633.1k)(102.4m)

Total Equity

465.2m419.3m386.3m

Debt to Equity Ratio

0.7 x0.8 x

Debt to Assets Ratio

0.3 x0.4 x

Financial Leverage

2.1 x2.1 x2.1 x

Quarterly

USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

32.2m63.1m63.7m98.0m

Accounts Receivable

72.7m56.9m68.1m33.9m

Prepaid Expenses

18.8m16.2m14.2m8.2m

Inventories

25.6m27.8m27.9m27.2m

Current Assets

149.3m164.0m174.0m167.3m

PP&E

31.3m30.7m31.1m30.3m

Goodwill

152.8m100.9m100.9m100.9m

Total Assets

855.5m776.1m643.8m494.2m

Accounts Payable

27.9m20.6m18.9m9.9m

Short-term debt

6.2m795.1k991.5k397.9k

Current Liabilities

115.6m96.5m97.9m78.6m

Long-term debt

310.0m271.8m271.8m271.4m

Total Debt

316.2m272.6m272.8m271.8m

Total Liabilities

439.0m394.9m385.9m352.5m

Common Stock

525.2k525.2k521.6k

Additional Paid-in Capital

491.1m492.4m489.8m

Retained Earnings

(1.9m)(108.6m)(233.2m)(346.4m)

Total Equity

415.5m381.2m257.9m141.7m

Financial Leverage

2.1 x2 x2.5 x3.5 x

Osmotica Pharmaceuticals Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

(41.8m)(45.2m)(109.4m)

Depreciation and Amortization

23.6m46.5m81.6m

Accounts Receivable

(12.5m)5.3m(17.0m)

Inventories

12.6m2.9m(7.4m)

Accounts Payable

(14.4m)588.2k(11.3m)

Cash From Operating Activities

(44.8m)57.8m37.6m

Purchases of PP&E

(13.9m)(6.9m)(4.1m)

Cash From Investing Activities

(453.5m)(19.4m)(4.1m)

Short-term Borrowings

(490.2k)(113.8k)

Long-term Borrowings

(3.8m)(338.8m)(56.3m)

Cash From Financing Activities

420.5m(23.3m)3.6m

Net Change in Cash

(77.7m)15.1m37.0m

Interest Paid

12.4m25.3m19.6m

Income Taxes Paid

8.5m17.6m2.6m

Quarterly

USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(42.3m)(3.6m)(6.2m)(130.9m)(244.3m)

Depreciation and Amortization

24.9m61.3m18.0m36.0m50.6m

Accounts Receivable

18.8m(33.8m)(378.4k)(11.6m)22.7m

Inventories

(132.9k)(8.6m)(3.4m)(3.5m)(2.9m)

Accounts Payable

(21.8m)(9.1m)(4.3m)(6.0m)(15.0m)

Cash From Operating Activities

36.0m7.2m(6.1m)(4.2m)32.9m

Purchases of PP&E

(7.1m)(3.0m)(634.6k)(2.1m)(3.0m)

Cash From Investing Activities

(7.1m)(3.0m)(634.6k)(2.1m)(3.1m)

Short-term Borrowings

(107.8k)(81.8k)

Long-term Borrowings

(484.3k)(31.3k)(63.8k)(97.0k)

Cash From Financing Activities

(16.3m)(5.7m)(1.0m)(846.6k)(2.8m)

Net Change in Cash

12.6m(1.5m)(7.8m)(7.1m)27.0m

Interest Paid

4.1m8.3m11.2m

Income Taxes Paid

214.8k365.3k544.6k

Osmotica Pharmaceuticals Ratios

USDY, 2019

EV/EBIT

-4 x

EV/CFO

14.9 x

Financial Leverage

3.5 x

Osmotica Pharmaceuticals Operating Metrics

Oct, 2018

Products

35

Osmotica Pharmaceuticals Employee Rating

2.613 votes
Culture & Values
2.6
Work/Life Balance
3.6
Senior Management
2.5
Salary & Benefits
2.7
Career Opportunities
2.3
Source